Tag - NMTR

Feature

9 Meters Biopharma targeting rare and unmet needs in GI disorders

By Leonard Zehr 9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and...

October 27, 2020

Markets

Brookline starts 9 Meters Biopharma at buy; PT $5

Brookline Capital Markets initiated coverage of 9 Meters Biopharma (NASDAQ:NMTR) with a “buy” rating and $5 price target. At midday on Aug. 20, the stock was quoted at 68 cents. 9 Meters is focused on two...

August 20, 2020

Developments

9 Meters doses first patients in Phase 1b/2a short bowel syndrome trial

9 Meters Biopharma (NASDAQ:NMTR) dosed the first patients in its Phase 1b/2a clinical trial evaluating NM-002 for the treatment of short bowel syndrome. Short bowel syndrome is a rare, life-threatening disease caused by...

July 21, 2020

Tag - NMTR

9 Meters Biopharma targeting rare and unmet needs in GI disorders

Brookline starts 9 Meters Biopharma at buy; PT $5

9 Meters doses first patients in Phase 1b/2a short bowel syndrome trial

General

More